The trials and hopes for drug development in sickle cell disease

British Journal of Haematology

Volumn 170, Issue 6, 2015, Pages 768-780

  Ataga, Kenneth I ^a   Stocker, Jonathan ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Selexys Pharmaceuticals   (United States)

Author keywords

Clinical trials; Drug development; Novel drugs; Sickle cell disease; Treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CETIEDIL; GLUTAMINE; HEMOGLOBIN F; HYDROXYUREA; METHYLPREDNISOLONE; NARCOTIC ANALGESIC AGENT; NITRIC OXIDE; PLACEBO; RIVIPANSEL; SENICAPOC; SODIUM CYANATE;

ANOREXIA; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; ANEMIA, SICKLE CELL; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANEMIA, SICKLE CELL; ANIMALS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84940604404     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13548     Document Type: Review

References (101)

1. Adams, R.J. & Brambilla, D.; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. (2005) Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine, 353, 2769-2778.
2. Adams, R., McKie, V., Nichols, F., Carl, E., Zhang, D.L., Figueroa, R., Litaker, M., Thompson, W. & Hess, D. (1992) The use of transcranial ultrasonography to predict stroke in sickle cell disease. New England Journal of Medicine, 326, 605-610.
3. Adams, R.J., McKie, V.C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F.T., Bonds, D.R. & Brambilla, D. (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine, 339, 5-11.
4. Alcaín, F.J., Löw, H., Crane, F.L. & Navas, P. (1994) Iron chelators hydroxyurea and bathophenanthroline disulfonate inhibit DNA synthesis by different pathways. Biochemistry and Molecular Biology International, 34, 273-279.
5. Anthi, A., Machado, R.F., Jison, M.L., Taveira-Dasilva, A.M., Rubin, L.J., Hunter, L., Hunter, C.J., Coles, W., Nichols, J., Avila, N.A., Sachdev, V., Chen, C.C. & Gladwin, M.T. (2007) Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 175, 1272-1279.
6. Ataga, K.I. & Key, N.S. (2007) Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology American Society of Hematology Educational Program, 91-96.
7. Ataga, K.I., Moore, C.G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A. & Orringer, E.P. (2006) Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. British Journal of Haematology, 134, 109-115.
8. Ataga, K.I., Smith, W.R., De Castro, L.M., Swerdlow, P., Saunthararajah, Y., Castro, O., Vichinsky, E., Kutlar, A., Orringer, E.P., Rigdon, G.C. & Stocker, J.W.; ICA-17043-05 investigators. (2008) Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood, 111, 3991-3997.
9. Ataga, K.I., Reid, M., Ballas, S.K., Yasin, Z., Bigelow, C., James, L.S., Smith, W.R., Galacteros, F., Kutlar, A., Hull, J.H. & Stocker, J.W.; ICA-17043-10 investigators. (2011) Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). British Journal of Haematology, 153, 92-104.
10. Ballas, S.K., Barton, F.B., Waclawiw, M.A., Swerdlow, P., Eckman, J.R., Pegelow, C.H., Koshy, M., Barton, B.A. & Bonds, D.R. (2006) Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes, 4, 59.
11. Barst, R.J., Mubarak, K.K., Machado, R.F., Ataga, K.I., Benza, R.L., Castro, O., Naeije, R., Sood, N., Swerdlow, P.S., Hildesheim, M. & Gladwin, M.T.; ASSET study group. (2010) Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology, 149, 426-435.
12. Belcher, J.D., Bryant, C.J., Nguyen, J., Bowlin, P.R., Kielbik, M.C., Bischof, J.C., Hebbel, R.P. & Vercellotti, G.M. (2003) Transgenic sickle mice have vascular inflammation. Blood, 101, 3953-3959.
13. Belcher, J.D., Mahaseth, H., Welch, T.E., Vilback, A.E., Sonbol, K.M., Kalambur, V.S., Bowlin, P.R., Bischof, J.C., Hebbel, R.P. & Vercellotti, G.M. (2005) Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. American Journal of Physiology Heart and Circulatory Physiology, 288, H2715-H2725.
14. Benjamin, L.J., Berkowitz, L.R., Orringer, E., Mankad, V.N., Prasad, A.S., Lewkow, L.M., Chillar, R.K. & Peterson, C.M. (1986) A collaborative, double-blind, randomized study of cetiedil citrate in sickle cell crisis. Blood, 67, 1442-1447.
15. Berkowitz, L.R. & Orringer, E.P. (1982) Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia. Blood Cells, 8, 283-288.
16. Bernini, J.C., Rogers, Z.R., Sandler, E.S., Reisch, J.S., Quinn, C.T. & Buchanan, G.R. (1998) Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood, 92, 3082-3089.
17. Biomarkers Definitions Working Group. (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics, 69, 89-95.
18. Boettger, M.K., Uceyler, N., Zelenka, M., Schmitt, A., Reif, A., Chen, Y. & Sommer, C. (2007) Differences in inflammatory pian in nNOS-, iNOS- and eNOS-deficient mice. European Journal of Pain, 11, 810-818.
19. Bridges, K.R., Barabino, G.D. & Brugnara, C. (1996) A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood, 88, 4701-4710.
20. Brousseau, D.C., Scott, J.P., Badaki, O., Darbari, D.S., Chumpitazi, C., Airewele, G.E., Ellison, A.M., Smith-Whitley, K., Mahajan, P., Sarnaik, S.A., Casper, T.C., Cook, L.J., Dean, M., Leonard, J., Hulbert, M.L., Powell, E., Liem, R.I., Hickey, R., Krishnamurti, L., Hillery, C.A. & Panepinto, J.A. (2014) Multi-center randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood (ASH Annual Meeting Abstracts), 124, 88.
21. Bunn, H.F. (1997) Pathogenesis and treatment of sickle cell disease. New England Journal of Medicine, 337, 762-769.
22. Cabannes, R., Lonsdorfer, J., Castaigne, J.P., Ondo, A., Plassard, A. & Zohoun, I. (1984) Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents and Actions. Supplements, 15, 199-212.
23. Castro, O.L., Gordeuk, V.R., Gladwin, M.T. & Steinberg, M.H. (2011) Senicapoc trial results support the existence of different sub-phenotypes of sickle cell disease with possible drug-induced phenotypic shifts. British Journal of Haematology, 155, 636-638.
24. Cerami, A. (1974) Review of the development of cyanate as a drug in the treatment of sickle cell anemia. Annals of the New York Academy of Sciences, 241, 538-544.
25. Chandrakasan, S. & Malik, P. (2014) Gene therapy for hemoglobinopathies: the state of the field and the future. Hematology Oncology Clinics of North America, 28, 199-216.
26. Chantrathammachart, P., Mackman, N., Sparkenbaugh, E., Wang, J.G., Parise, L.V., Kirchhofer, D., Key, N.S. & Pawlinski, R. (2012) Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood, 120, 636-646.
27. Chaplin, Jr, H., Alkjaersig, N., Fletcher, A.P., Michael, J.M. & Joist, J.H. (1980) Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thrombosis and Haemostasis, 43, 218-221.
28. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P. & Bonds, D.R. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New England Journal of Medicine, 332, 1317-1322.
29. Cokic, V.P., Smith, R.D., Beleslin-Cokic, B.B., Njoroge, J.M., Miller, J.L., Gladwin, M.T. & Schechter, A.N. (2003) Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. Journal of Clinical Investigation, 111, 231-239.
30. Cooperative Urea Trials Group. (1974) Clinical trials of therapy for sickle cell vaso-occlusive crises. Journal of the American Medical Association, 228, 1120-1124.
31. De Castro, L.M., Jonassaint, J.C., Graham, F.L., Ashley-Koch, A. & Telen, M.J. (2008) Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. American Journal of Hematology, 83, 19-25.
32. De Caterina, R., Libby, P., Peng, H.B., Thannickal, V.J., Rajavashisth, T.B., Gimbrone, Jr, M.A., Shin, W.S. & Liao, J.K. (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. Journal of Clinical Investigation, 96, 60-68.
33. DeBaun, M.R., Gordon, M., McKinstry, R.C., Noetzel, M.J., White, D.A., Sarnaik, S.A., Meier, E.R., Howard, T.H., Majumdar, S., Inusa, B.P., Telfer, P.T., Kirby-Allen, M., McCavit, T.L., Kamdem, A., Airewele, G., Woods, G.M., Berman, B., Panepinto, J.A., Fuh, B.R., Kwiatkowski, J.L., King, A.A., Fixler, J.M., Rhodes, M.M., Thompson, A.A., Heiny, M.E., Redding-Lallinger, R.C., Kirkham, F.J., Dixon, N., Gonzalez, C.E., Kalinyak, K.A., Quinn, C.T., Strouse, J.J., Miller, J.P., Lehmann, H., Kraut, M.A., Ball, Jr, W.S., Hirtz, D. & Cassella, J.F. (2014) Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine, 371, 699-710.
34. DeMuro, C., Clark, M., Doward, L., Evans, E., Mordin, M. & Gnanasakthy, A. (2013) Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). Value in Health, 16, 1150-1155.
35. Elmariah, H., Garrett, M.E., De Castro, L.M., Jonassaint, J.C., Ataga, K.I., Eckman, J.R., Ashley-Koch, A.E. & Telen, M.J. (2014) Factors associated with survival in a contemporary adult sickle cell disease cohort. American Journal of Hematology, 89, 530-535.
36. Ferrantino, M. & White, R.J. (2011) Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 12, 2583-2593.
37. Fitzhugh, C.D., Abraham, A.A., Tisdale, J.F. & Hsieh, M.M. (2014) Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions. Hematology and Oncology Clinics of North America, 28, 1171-1185.
38. Frenette, P.S. (2002) Sickle cell vaso-occlusion: multistep and multicellular paradigm. Current Opinion in Hematology, 9, 101-106.
39. Gaston, M.H., Verter, J.I., Woods, G., Pegelow, C., Kelleher, J., Presbury, G., Zarkowsky, H., Vichinsky, E., Iyer, R., Lobel, J.S., Diamond, S., Holbrook, C.T., Gill, F.M., Ritchey, K. & Falletta, J.M.; For the Prophylactic Penicillin Study Group. (1986) Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. New England Journal of Medicine, 314, 1593-1599.
40. Gillette, P.N., Peterson, C.M., Lu, Y.S. & Cerami, A. (1974) Sodium cyanate as a potential treatment for sickle-cell disease. New England Journal of Medicine, 290, 654-660.
41. Gladwin, M.T. (2006) Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. Journal of Clinical Investigation, 116, 2330-2332.
42. Gladwin, M.T., Shelhamer, J.H., Ognibene, F.P., Pease-Fye, M.E., Nichols, J.S., Link, B., Patel, D.B., Jankowski, M.A., Pannell, L.K., Schechter, A.N. & Rodgers, G.P. (2002) Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. British Journal of Haematology, 116, 436-444.
43. Gladwin, M.T., Sachdev, V., Jison, M.L., Shizukuda, Y., Plehn, J.F., Minter, K., Brown, B., Coles, W.A., Nichols, J.S., Ernst, I., Hunter, L.A., Blackwelder, W.C., Schechter, A.N., Rodgers, G.P., Castro, O. & Ognibene, F.P. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. New England Journal of Medicine, 350, 886-895.
44. Gladwin, M.T., Kato, G.J., Weiner, D., Onyekwere, O.C., Dampier, C., Hsu, L., Hagar, R.W., Howard, T., Nuss, R., Okam, M.M., Tremonti, C.K., Berman, B., Villella, A., Krisnamurti, L., Lanzkron, S., Castro, O., Gordeuk, V.R., Coles, W.A., Peters-Lawrence, M., Nichols, J., Hall, M.K., Hildesheim, M., Blackwelder, W.C., Baldassarre, J. & Cassella, J.F.; DeNOVO Investigators. (2011) Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. Journal of the American Medical Association, 305, 893-902.
45. Glover, R.E., Ivy, E.D., Orringer, E.P., Maeda, H. & Mason, R.P. (1999) Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Molecular Pharmacology, 55, 1006-1010.
46. Greenberg, J., Ohene-Frempong, K., Halus, J., Way, C. & Schwartz, E. (1983) Trial of low doses of aspirin as prophylaxis in sickle cell disease. Journal of Pediatrics, 102, 781-784.
47. Griffin, T.C., McIntire, D. & Buchanan, G.R. (1994) High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. New England Journal of Medicine, 330, 733-737.
48. Harkness, D.R. & Roth, S. (1975) Clinical evaluation of cyanate in sickle cell anemia. Progress in Hematology, 9, 157-184.
49. Hassell, K.L. (2010) Population estimates of sickle cell disease in the U.S. American Journal of Preventive Medicine, 38, S512-S521.
50. Hillery, C.A., Du, M.C., Wang, W.C. & Scott, J.P. (2000) Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. British Journal of Haematology, 109, 322-327.
51. Hrometz, S.L. & Shields, K.M. (2008) Role of ambrisentan in the management of pulmonary hypertension. Annals of Pharmacotherapy, 42, 1653-1659.
52. Hsieh, M.M., Fitzhugh, C.D., Weitzel, R.P., Link, M.E., Coles, W.A., Zhao, X., Rodgers, G.P., Powell, J.D. & Tisdale, J.F. (2014) Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. Journal of the American Medical Association, 312, 48-56.
53. Huang, J., Yakubu, M., Kim-Shapiro, D.B. & King, S.B. (2006) Rat liver-mediated metabolism of hydroxyurea to nitric oxide. Free Radical Biology and Medicine, 40, 1675-1681.
54. Humphries, C. (2014) Drug development: a complicated path. Nature, 515, S4-S5.
55. Kato, G.J., Gladwin, M.T. & Steinberg, M.H. (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews, 21, 37-47.
56. Kauf, T.L., Coates, T.D., Huazhi, L., Mody-Patel, N. & Hartzema, A.G. (2009) The cost of health care for children and adults with sickle cell disease. American Journal of Hematology, 84, 323-327.
57. King, S.B. (2004) Nitric oxide production from hydroxyurea. Free Radical Biology and Medicine, 37, 737-744.
58. Lanzkron, S., Carroll, C.P. & Haywood, Jr, C. (2013) Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Reports, 128, 110-116.
59. Levin, E.R., Gardner, D.G. & Samson, W.K. (1998) Natriuretic peptides. New England Journal of Medicine, 339, 321-328.
60. Mabaera, R., West, R.J., Conine, S.J., Macari, E.R., Boyd, C.D., Engman, C.A. & Lowrey, C.H. (2008) A cell stress signaling model of fetal hemoglobin induction; what doesn't kill red blood cells makes them stronger. Experimental Hematology, 36, 1057-1072.
61. Machado, R.F., Martyr, S., Kato, G.J., Barst, R.J., Anthi, A., Robinson, M.R., Hunter, L., Coles, W., Nichols, J., Hunter, C., Sachdev, V., Castro, O. & Gladwin, M.T. (2005) Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. British Journal of Haematology, 130, 445-453.
62. Machado, R.F., Barst, R.J., Yovetich, N.A., Hassell, K.L., Kato, G.J., Gordeuk, V.R., Gibbs, J.S., Little, J.A., Schraufnagel, D.E., Krishnamurti, L., Girgis, R.E., Morris, C.R., Rosenzweig, E.B., Badesch, D.B., Lanzkron, S., Onyekwere, O., Castro, O.L., Sachdev, V., Waclawiw, M.A., Woolson, R., Goldsmith, J.C. & Gladwin, M.T. (2011) Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood, 118, 855-864.
63. Manwani, D. & Frenette, P.S. (2013) Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood, 122, 3892-3898.
64. McGann, P.T. & Ware, R.E. (2011) Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Current Opinion in Hematology, 18, 158-165.
65. Minniti, C.P., Wilson, J., Mendelsohn, L., Rigdon, G.C., Stocker, J.W., Remaley, A.T. & Kato, G.J. (2011) Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia. British Journal of Haematology, 115, 634-635.
66. Modell, B. & Darlison, M. (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization, 86, 480-487.
67. Morris, C.R., Kuypers, F.A., Lavrisha, L., Ansari, M., Sweeters, N., Stewart, M., Gildengorin, G., Neumayr, L. & Vichinsky, E.P. (2013) A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica, 98, 1375-1382.
68. Nagel, R.L., Bookchin, R.M., Johnson, J., Labie, D., Wajcman, H., Isaac-Sodeye, W.A., Honig, G.R., Schiliro, G., Crookston, J.H. & Matsutomo, K. (1979) Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proceedings of the National Academy of Sciences of United States of America, 76, 670-672.
69. Nicholson, D.H., Harkness, D.R., Benson, W.E. & Peterson, C.M. (1976) Cyanate-induced cataracts in patients with sickle-cell hemoglobinopathies. Archives of Ophthalmology, 94, 927-930.
70. Niihara, Y., Koh, H.A., Tran, L., Razon, R., Macan, H., Stark, C., Wun, T. & Adams-Graves, P. (2014) A phase 3 study of L-glutamine therapy for sickle cell anemia and sickle ß0-thalassemia. Blood (ASH Annual Meeting Abstracts), 124, 86.
71. Odièvre, M.H., Bony, V., Benkerrou, M., Lapoumeroulie, C., Alberti, C., Ducrocq, R., Jacqz-Aigrain, E., Elion, J. & Cartron, J.P. (2008) Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica, 93, 502-510.
72. Orringer, E.P., Casella, J.F., Ataga, K.I., Koshy, M., Adams-Graves, P., Luchtman-Jones, L., Wun, T., Watanabe, M., Shafer, F., Kutlar, A., Abboud, M., Steinberg, M., Adler, B., Swerdlow, P., Terregino, C., Saccente, S., Files, B., Ballas, S., Brown, R., Wojtowicz-Praga, S. & Grindel, J.M. (2001) Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. Journal of the American Medical Association, 286, 2099-2106.
73. Osamo, N.O., Photiades, D.P. & Famodu, A.A. (1981) Therapeutic effect of aspirin in sickle cell anemia. Acta Haematologica, 66, 102-107.
74. Pakbaz, Z. & Wun, T. (2014) Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics. Hematology and Oncology Clinics of North America, 28, 355-374.
75. Palmer, R.M., Ashton, D.S. & Moncada, S. (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature, 333, 664-666.
76. Panepinto, J.A. (2012) Health-related quality of life in patients with hemoglobinopathies. Hematology/the Education Program of the American Society of Hematology, 2012, 284-289.
77. Panepinto, J.A. & Bonner, M. (2012) Health-related quality of life in sickle cell disease: past, present, and future. Pediatric and Blood Cancer, 59, 377-385.
78. Parent, F., Bachir, D., Inamo, J., Lionnet, F., Driss, F., Loko, G., Habibi, A., Bennani, S., Savale, L., Adnot, S., Maitre, B., Yaici, A., Hajji, L., O'Callaghan, D.S., Clerson, P., Girot, R., Galacteros, F. & Simonneau, G. (2011) A hemodynamic study of pulmonary hypertension in sickle cell disease. New England Journal of Medicine, 365, 44-53.
79. Pauling, L., Itano, H.A., Singer, S.J. & Wells, I.C. (1949) Sickle cell anemia, a molecular disease. Science, 110, 543-548.
80. Peterson, C.M., Tsairis, P., Ohnishi, A., Lu, Y.S. & Grady, R. (1974) Sodium cyanate induced polyneuropathy in patients with sickle cell disease. Annals of Internal Medicine, 81, 152-158.
81. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine, 330, 1639-1644.
82. Qari, M.H., Aljaouni, S.K., Alardawi, M.S., Fatani, H., Alsayes, F.M., Zografos, P., Alsaigh, M., Alalfi, A., Alamin, M. & Mousa, S.A. (2007) Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis, 98, 392-396.
83. Rees, D.C. & Gibson, J.S. (2011) Biomarkers in sickle cell disease. British Journal of Haematology, 156, 433-445.
84. Rees, D.R., Williams, T.N. & Gladwin, M.T. (2010) Sickle-cell disease. Lancet, 376, 2018-2031.
85. Reiter, C.D., Wang, X., Tanus-Santos, J.E., Hogg, N., Cannon, 3rd, R.O., Schechter, A.N. & Gladwin, M.T. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nature Medicine, 8, 1383-1389.
86. Repka, T. & Hebbel, R.P. (1991) Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. Blood, 78, 2753-2758.
87. Schaer, D.J., Buehler, P.W., Alayash, A.I., Belcher, J.D. & Vercellotti, G.M. (2013) Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood, 121, 1276-1284.
88. Schmidtko, A., Tegeder, I. & Geisslinger, G. (2009) No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends in Neurosciences, 32, 339-346.
89. Smith, W.R., Penberthy, L.T., Bovbjerg, V.E., McClish, D.K., Roberts, J.D., Dahman, B., Aisiku, I.P., Levenson, J.L. & Roseff, S.D. (2008) Daily assessment of pain in adults with sickle cell disease. Annals of Internal Medicine, 148, 94-101.
90. Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M.A., Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA, 289, 1645-1651.
91. Steinberg, M.H., McCarthy, W.F., Castro, O., Ballas, S.K., Armstrong, F.D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L & Waclawiw, M.A.; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematology, 85, 403-408.
92. Steiner, C.A. & Miller, J.L. (2006) Sickle cell disease patients in US hospitals, 2004. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Agency for Health Care Policy and Research (US), Rockville, MD.
93. Telen, M.J., Wun, T., McCavit, T.L., De Castro, L.M., Krishnamurti, L., Lanzkron, S., Hsu, L.L., Smith, W.R., Rhee, S., Magnani, J.L. & Thackray, H. (2015) Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood, 125, 2656-2664.
94. Thornburg, C.D., Calatroni, A. & Panepinto, J.A. (2011) Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. Journal of Pediatric Hematology and Oncology, 33, 251-254.
95. Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulos, A., Loukopoulos, D. & Terpos, E. (2010) The effect of prolonged administration of hydroxyurea on morbidity in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, 115, 2354-2363.
96. Wallace, K.L., Marshall, M.A., Ramos, S.I., Lannigan, J.A., Field, J.J., Strieter, R.M. & Linden, J. (2009) NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood, 114, 667-676.
97. Wang, W.C., Ware, R.E., Miller, S.T., Iyer, R.V., Cassella, J.F., Minniti, C.P., Rana, S., Thornburg, C.D., Rogers, Z.R., Kalpatthi, R.V., Barredo, J.C., Brown, R.C., Sarnaik, S.A., Howard, T.H., Wynn, L.W., Kutlar, A., Armstrong, F.D., Files, B.A., Goldsmith, J.C., Waclawiw, M.A., Huang, X. & Thompson, B.W.; BABY HUG investigators. (2011a) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet, 377, 1663-1672.
98. Wang, W., Brugnara, C., Snyder, C., Wynn, L., Rogers, Z., Kalinyak, K., Brown, C., Qureshi, A., Bigelow, C., Neumayr, L., Smith-Whitley, K., Chu, D.H.K., Delahunty, M., Woolson, R., Steinberg, M., Telen, M. & Kesler, K. (2011b) The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology, 152, 771-776.
99. Wood, K.C., Hebbel, R.P. & Granger, D.N. (2005) Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. The Faseb Journal, 19, 989-991.
100. Yawn, B.P., Buchanan, G.R., Afenyi-Annan, A.N., Ballas, S.K., Hassell, K.L., James, A.H., Jordan, L., Lanzkron, S.M., Lottenberg, R., Savage, W.J., Tanabe, P.J., Ware, R.E., Murad, M.H., Goldsmith, J.C., Ortiz, E., Fulwood, R., Horton, A. & John-Sowah, J. (2014) Management of patients with sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA, 312, 1033-1048.
101. Zago, M.A., Costa, F.F., Ismael, S.J., Tone, L.G. & Bottura, C. (1984) Treatment of sickle cell diseases with aspirin. Acta Haematologica, 72, 61-64.